Compare TG Therapeutics Inc (TGTX) vs PT Telekomunikasi Indonesia Tbk (TLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs PT Telekomunikasi Indonesia Tbk — how do they compare? TG Therapeutics Inc trades at $53.34 (market cap $8.11B), while PT Telekomunikasi Indonesia Tbk trades at $12.96 (market cap $12.43B). The key difference: PT Telekomunikasi Indonesia Tbk is the larger of the two by market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.48% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 15 Days and PT Telekomunikasi Indonesia Tbk for 0 Days on average.
| TGTX | TLK | |
|---|---|---|
Market Cap | $8.11B | $12.43B |
Volume | 1,505,658 | 1,067,041 |
Sector | Health | Media |
52-Week High | $59.06 | $23.43 |
52-Week Low | $26.94 | $12.42 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $8.31B | $13.80B |
Dividend Yield | — | 9.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $52.95, up 1.46% today, but faces bearish technical signals with recent earnings misses. The company shows strong profitability with 55.22% net margin and 100.28% ROE, while revenue growth continues with BRIUMVI capturing market share. Recent news includes shareholder litigation investigation and buyout speculation.
Despite earnings volatility, TGTX maintains strong fundamentals with analyst consensus at Buy (84.62%) and $80.50 price target. Key risks include ongoing legal scrutiny and execution on BRIUMVI growth, while institutional accumulation signals confidence in long-term prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About PT Telekomunikasi Indonesia Tbk
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →
